MRSA news from FierceBiotech
NewsBasilea shares plunge on antibiotic delay
Switzerland's Basilea took its turn on the public markets' whipping post, shedding 27 percent of share value after announcing that its antibiotic ceftobiprole had failed to quickly win over FDA Read more...
Cepheid cashes in on MRSA trends--for now
With cases of antibiotic-resistant MRSA multiplying and fear of the superbug rising, Cepheid Read more...
FDA to review Theravance's telavancin response
More news in Theravance's ongoing battle to win approval for its antibiotic telavancin: the FDA has accepted the company's response to the Read more...
FDA cancels meeting as hopes rise for Basilea
The FDA has canceled a scheduled advisory board meeting on Basilea's ceftobiprole antibiotic, a move that Read more...
ALSO NOTED: Ventana and Roche forge confidentiality agreement; Rigel wins $3M payment; and much more...
> Ventana Medical Systems and Roche have made nice over a confidentiality agreement, raising the prospects of a takeover. One analyst says that Ventana would likely fetch more than $87 a share. Read more...
Dry antibiotic pipeline concerns infectious disease experts
The Infectious Diseases Society of America has been beating the drum over a paucity of new antibiotic approvals. With drug developers lured by bigger margins in other disease categories, drug Read more...
Basilea reports positive Phase III antibiotic data
A late-stage trial of the experimental antibiotic ceftobiprole, which is being jointly developed by Read more...
WHO: Infectious disease a growing threat
A new report from the World Health Organization is sounding the alarm on the serious threat the world faces from rapidly spreading infectious disease. New disease are emerging--such as AIDS, Ebola Read more...
| Press ReleasesPRESS RELEASE: Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections Scientists Identify Factor Key to Severity of Community-Associated Methicillin-Resistant Staph Infections Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium Read more... PRESS RELEASE: CDC estimates 94,000 invasive drug-resistant staph infections occurred in the U.S. in 2005 CDC estimates 94,000 invasive drug-resistant staph infections occurred in the U.S. in 2005 Study establishes baseline for MRSA infection estimates Methicillin–resistant staph aureus (MRSA) caused Read more... |
Get more MRSA coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets